Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer

Reply to: Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer

Saved in:

Bibliographic Details
Main Authors:	Kumar Prabhash, Roshan Pawar, Vijaya Gunjal
Format:	Article
Language:	English
Published:	American Society of Clinical Oncology 2025-07-01
Series:	JCO Global Oncology
Online Access:	https://ascopubs.org/doi/10.1200/GO-25-00216
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Critical Review: Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer
by: Anita Ramesh
Published: (2025-07-01)

Cetuximab and Paclitaxel Drug Response in Head and Neck Tumor Stem Cells
by: Vilson Serafim Júnior, et al.
Published: (2025-02-01)

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
by: Jiefu Zhou, et al.
Published: (2025-03-01)

Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)

Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain
by: Ruth Alvarez Cabellos, et al.
Published: (2025-01-01)

Unilateral Cervical Polyneuropathies following Concurrent Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer
by: Alhasan Elghouche, et al.
Published: (2016-01-01)

Practical Consensus Guidelines on the Use of Cetuximab in Head and Neck Squamous Cell Carcinoma (HNSCC)
by: Purvish M. Parikh, et al.
Published: (2025-01-01)

Two Cases of Pneumatosis Intestinalis during Cetuximab Therapy for Advanced Head and Neck Cancer
by: James A. Miller, et al.
Published: (2015-01-01)

The role of cetuximab in the treatment of patients with squamous cell carcinoma of the head and neck: resolution of the Expert Council
Published: (2019-01-01)

Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab
by: Xuefeng Wang, et al.
Published: (2025-03-01)

Chemotherapy with cetuximab in head and neck squamous cell carcinoma: immunological aspects and markers of treatment effectiveness in clinical practice
by: A. I. Stukan, et al.
Published: (2024-06-01)

Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer
by: Y. Pointreau, et al.
Published: (2025-03-01)

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

Preclinical investigation of anti-tumor efficacy of allogeneic natural killer cells combined with cetuximab for head and neck squamous cell carcinoma
by: Chaeyeon Kim, et al.
Published: (2025-03-01)

Cetuximab-Associated Crescentic Diffuse Proliferative Glomerulonephritis
by: Sukesh Manthri, et al.
Published: (2017-01-01)

Targeted siRNA Delivery Using Cetuximab‐Conjugated Starch for Epidermal Growth Factor Receptor‐Driven Head and Neck Squamous Cell Carcinoma
by: Chen Benafsha, et al.
Published: (2025-07-01)

Inhibition of Glutamine Uptake Improves the Efficacy of Cetuximab on Gastric Cancer
by: Huanrong Ma PhD, et al.
Published: (2021-09-01)

[Comment] Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): a randomized controlled trial
by: Zhang Rongxin
Published: (2024-08-01)

A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer
by: Guangnan Yao, et al.
Published: (2025-06-01)

Use of Cetuximab in Combination with Cisplatin and Adjuvant Pelvic Radiation for Stage IIIB Vulvar Carcinoma
by: Jennifer Bergstrom, et al.
Published: (2015-01-01)

Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab
by: Jeffrey Chi, et al.
Published: (2020-01-01)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
by: Roberto Benelli, et al.
Published: (2022-12-01)

Pneumatosis Cystoides Intestinalis after Cetuximab Chemotherapy for Squamous Cell Carcinoma of Parotid Gland
by: Christos Petrides, et al.
Published: (2015-01-01)

NDRG1 enhances the sensitivity to Cetuximab by promoting Stat1 ubiquitylation in colorectal cancer
by: Guang Yang, et al.
Published: (2025-06-01)

Single‐cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer
by: Shiyun Chen, et al.
Published: (2025-01-01)

Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges
by: Bo Pei PhD, et al.
Published: (2025-05-01)

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer
by: Shiyun Chen, et al.
Published: (2025-05-01)

[Comment] Compara tive effectiveness of bevacizumab versus cetuximab in meta static colorectal cancer patients without primary tumor resec tion
by: Li Yingru, et al.
Published: (2022-08-01)

Combination of concurrent targeted and immune-therapy with nivolumab and cetuximab: new perspectives for squamous cell carcinoma treatment
by: A. M. Mudunov, et al.
Published: (2020-11-01)

Corneal Perforation during Combination Chemotherapy including Cetuximab in a Patient with a History of Herpetic Keratitis
by: Keiichi Aomatsu, et al.
Published: (2020-01-01)

Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report
by: Taro Fukui, et al.
Published: (2019-10-01)

Temporary hypocalcemia induced by cetuximab sarotalocan without hypomagnesemia in a patient with hypoparathyroidism: a novel case report
by: Moeko Kado, et al.
Published: (2025-07-01)

Effect of toripalimab plus cetuximab combined with radiotherapy on patient with locally advanced high-grade parotid mucoepidermoid carcinoma
by: Yubin Wu, et al.
Published: (2025-03-01)

Excellent response of cetuximab plus chemotherapy after pembrolizumab monotherapy in metastatic hypopharyngeal cancer: A case report
by: Anh Tuan Pham, et al.
Published: (2025-03-01)

MiR-135b-5p promotes cetuximab resistance in colorectal cancer by regulating FOXN3
by: Chun Peng, et al.
Published: (2024-12-01)

BRAF V600E-mutant colorectal cancer with CNS metastases treated successfully with encorafenib, binimetinib and cetuximab
by: Toru Imai, et al.
Published: (2024-12-01)

Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
by: Manish Kumar, et al.
Published: (2024-11-01)

Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
by: Khadijeh Falahzadeh, et al.
Published: (2024-09-01)

Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)

Safety and Feasibility of Blockade of NK Group-2 Member-A Receptor in Natural Killer Cells Combined with Cetuximab Antibody in Patients with Advanced Gastric Adenocarcinoma
by: Maryam Samareh-Salavatipour, et al.
Published: (2025-04-01)